Roche’s Foundation Medicine rebranded Saga Diagnostics’ minimal residual disease test after the $595 million acquisition, renaming the assay to FoundationOne MRD and signaling a push into indications beyond its initial breast cancer use. The test uses patient tissue to derive a structural-variant fingerprint via whole-genome sequencing, then converts it into a digital PCR assay to track MRD from circulating tumor DNA. Foundation Medicine said the structural-variant approach is intended to improve sensitivity and specificity over assays focused on point mutations, which may change over time with disease evolution or sequencing error. The company also emphasized that the patient-specific workflow can be run at any lab and takes about 48 hours. The move is likely to expand the MRD market footprint by targeting additional tumor types where structural-variant tracking and digital PCR support scalable monitoring.